Imagine the simple joy of dining out suddenly tainted with a layer of quiet dread. For millions on GLP-1 medications like Ozempic and Wegovy, this is the new reality. The menu, once a map of possibilities, becomes a maze of questions: "What can I actually eat? What fits my new needs?" Don't worry, this isn't a niche problem, but an actual cultural tidal wave.
The global market for these drugs, valued at $54.8 billion in 2024, is projected by BCC Research to skyrocket to an astonishing $268.4 billion by 2030. This explosive growth created an urgent void for a smart, real-time dining solution.
Stepping in to fill it is Menu-Order AI app, which has quickly become the indispensable dining companion for this massive new consumer demographic.




